on NANOBIOTIX (EPA:NANO)
Nanobiotix Unveils Phase 1 Results at European Lung Cancer Congress
Nanobiotix announced the presentation of data from two Phase 1 studies of JNJ-1900 (NBTXR3) at the European Lung Cancer Congress. The first study, led by Dr. Saumil Gandhi, evaluates the safety and efficacy of JNJ-1900 in patients with re-irradiation in locoregionally relapsed non-small cell lung cancer (NSCLC). The results include progression-free survival data.
The second study, presented by Dr. Colette Shen, examines the safety and feasibility of injecting JNJ-1900 with nivolumab or pembrolizumab to treat lung metastases from NSCLC or other solid tumors. Nanobiotix, a pioneer in the use of nanoparticles, continues to explore innovative cancer therapies.
R. H.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all NANOBIOTIX news